교모세포종(GBM) : 역학 보고서 및 전망

Glioblastoma multiforme (GBM) is a highly aggressive form of glioma, a cancer arising from astrocytes, and is the most common type of brain tumor in adults (Kanderi et al., 2024). The distinction of "multiforme" comes from the wide range of genetic expressions characteristic of the cancer, complicating treatment (Kanderi et al., 2024). Glioblastoma multiforme is currently incurable, with a median survival time of 15 months and a 7.2% five-year survival rate (Kanderi et al., 2024). Gold standard treatment is a combination of surgical resection, followed by the "Stupp protocol" comprising radiotherapy and temozolomide (Kanderi et al., 2024).

In 2021 the WHO differentiated between two types of glioblastomas - isocitrate dehydrogenase (IDH)-wild type and IDH-mutant. The new classification listed IDHWT as glioblastoma and re-labeled IDH-mutant as diffuse astrocytoma grade IV (Stoyanov et al., 2022). For the purposes of this model, both IDH-WT and IDHmutant forms are classified as GBM, though the differentiation is noted in relevant segmentations.

Scope

• The model includes a 10-year epidemiological forecast for the diagnosed incident cases and five-year diagnosed prevalent cases of GBM. Diagnosed incident cases are segmented by age (starting from 0 up to 85 years and older by 5-year age groups) and sex. Additionally, the diagnosed incident cases of GBM are segmented by origin (primary or secondary), biomarker (MGMT methylated/unmethylated, EGFR VIII positive, EGFR amplification positive), and mutation (IHD1/IHD2 mutation, TERT promoter mutation, BRAF-V600E mutation, HLA-A2 mutation, and NTRK mutation).
• The model also includes includes a forecast of diagnosed incident cases of central nervous system (CNS) cancer by subtype (glioblastoma, meningioma, ependymoma, oligodendroglioma, CNS lymphoma, and other).

Reasons to Buy

• The GBM Epidemiology series will allow you to:
• Develop business strategies by understanding the trends shaping and driving the global GBM markets.
• Quantify patient populations in the global GBM markets to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GBM therapeutics in each of the markets covered.
• Understand the magnitude of the GBM population by age, sex, origin, biomarker, and mutation.

Table of Contents

Table of Contents (PowerPoint Deck)

1. Preface

• 1.1. Contents

2. Executive Summary

3. Disease Overview

• 3.1. Background
• 3.2. Risk Factors and Comorbidities

4. Epidemiological Forecast

• 4.1 Diagnosed Incident Cases of GBM, N, All Ages, Men and Women, 2025-35
• 4.2 Age-Specific Trends in Diagnosed Incident Cases of GBM, N, Men and Women, 2025
• 4.3 Sex-Specific Diagnosed Incident Cases of GBM, N, All Ages, 2025
• 4.4 Trends of Diagnosed Incidence of GBM, Cases per 100,000 Population, All Ages, 2015-35
• 4.5 Diagnosed Incident Cases of Central Nervous System (CNS) Cancer by Subtype, N, All Ages, 2025
• 4.6 Diagnosed Incident Cases of GBM by Epidemiology of GBM Origin, N, All Ages, 2025
• 4.7 Diagnosed Incident Cases of GBM by Biomarker, N, All Ages, 2025
• 4.8 Diagnosed Incident Cases of GBM by Mutation, N, All Ages, 2025
• 4.9 Five-Year Diagnosed Prevalent Cases of GBM, N, All Ages, Men and Women, 2025-35

5 Sources and Methodology

• 5.1. Sources and Methodology for GBM Incidence
• 5.2 Sources and Methodology for GBM Five-Year Prevalence
• 5.3 Sources and Methodology for GBM - Diagnosed Incident Cases of GBM
• 5.4 Sources and Methodology for GBM - Diagnosed Incident Cases of CNS Cancer by Subtype
• 5.5 Sources and Methodology for GBM - Diagnosed Incident Cases of GBM by Origin
• 5.6 Sources and Methodology for GBM - Diagnosed Incident Cases of GBM by Biomarker
• 5.7 Sources and Methodology for GBM - Diagnosed Incident Cases of GBM by Mutation
• 5.8 Sources and Methodology for GBM - Five-Year Diagnosed Prevalent Cases of GBM

6. Discussion

• 6.1. Epidemiological Forecast Insight
• 6.2. Strengths and Limitations

7. Appendix

• 7.1. Bibliography
• 7.2. About the Authors

8. Contact Us